{
    "clinical_study": {
        "@rank": "143010", 
        "arm_group": [
            {
                "arm_group_label": "placebo, response, adverse effect", 
                "arm_group_type": "Placebo Comparator", 
                "description": "children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children  hospital Israel Haifa  that are being treated  with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with  no interventions and will be required to record all  there FMF episodes and their GIT adverse effect, in the second period  the patients will be randomly divided into  two groups patients that will received  placebo arm one and  patients that will receive probiotics arm two."
            }, 
            {
                "arm_group_label": "probiotic, response, adverse effect", 
                "arm_group_type": "Active Comparator", 
                "description": "children (5-17 years old) with FMF that are currently followed in the pediatric rheumatology clinic at Mayer children  hospital Israel Haifa  that are being treated  with colchicine and suffering from either gastrointestinal adverse effect or partial response to colchicine.in the first 3 month patients will be followed with  no interventions and will be required to record all  there FMF episodes and their GIT adverse effect, in the second period  the patients will be randomaly devided into  two groups patients that will received  placebo arm one and  patients that will receive probiotics arm two."
            }
        ], 
        "brief_summary": {
            "textblock": "Colchicine is the drug of choice to treat patients with Familial Mediterranean Fever (FMF ),\n      some of the patients treated with colchicine may suffer from gastrointestinal (GIT) adverse\n      effect such as diarrhea and abdominal pain especially in the higher dose.\n\n      5-10% of the patients with FMF that have been treated with colchicine may have partial or no\n      response to this therapy.\n\n      Aim of our study: the aim of our study is :.1to evaluate the efficacy of probiotics in\n      reducing the number of adverse effect in patients with FMF that are being treated with\n      colchicine and suffering from GIT adverse effect.\n\n      .2 To evaluate the efficacy of probiotics in reducing the number of FMF attacks in children\n      with FMF that has been treated with colchicine with only partial response.\n\n      Methods: the study will be done among children (5-17 years old) with FMF that are currently\n      followed in the pediatric rheumatology clinic at Mayer children  hospital Israel Haifa  that\n      are being treated  with colchicine and suffering from either GIT adverse effect or partial\n      response to colchicine.\n\n      The study is design to be double blind  placebo control, in the first 3 month patients will\n      be with no therapy and will be required to record all  there FMF episodes and their GIT\n      adverse effect, in the second period  the patients will be randomly divided into  two groups\n      1.patients that will received  placebo (group 1) and the 2. Probiotics group - patients will\n      received probiotics (Bio -25 including  11 types of bacteria L.acidophilus, B.bifidum ,\n      L.rhamnosus, L.lactis, L.casei, B.breve, B.thermophilus, B.longum, L.paracseis, L.plantarum,\n      B.infantis), both for three month, during this period patient will be required to record\n      their gastrointestinal  symptoms and other symptoms that may be related to FMF."
        }, 
        "brief_title": "The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever.", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Familial Mediterranean Fever (FMF )", 
        "condition_browse": {
            "mesh_term": [
                "Brucellosis", 
                "Fever", 
                "Familial Mediterranean Fever", 
                "Hereditary Autoinflammatory Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of FMF\n\n          -  Age 5-18 years\n\n          -  Colchicine therapy\n\n          -  Gastrointestinal adverse effect or  recurrent FMF  attacks on colchicine\n\n        Exclusion Criteria:\n\n        \u2022 Severe immune deficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02021084", 
            "org_study_id": "0173-13-RMB CTIL"
        }, 
        "intervention": [
            {
                "arm_group_label": "probiotic, response, adverse effect", 
                "description": "Probiotics group - patients will received probiotics Bio -25 including  11 types of bacteria total of 25 billion germs in each capsule, patients will received one capsule a day for 3 month.", 
                "intervention_name": "probiotic", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Bio 25"
            }, 
            {
                "arm_group_label": "placebo, response, adverse effect", 
                "description": "Placebo  group - patients will received placebo patients will received one capsule a day for 3 month.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Colchicine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Familial Mediterranean Fever (FMF), probiotics", 
        "lastchanged_date": "December 26, 2013", 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "yonatanbutbul@gmail.com", 
            "last_name": "Yonatan Butbul, M.D", 
            "phone": "972-54-3359151"
        }, 
        "overall_contact_backup": {
            "email": "r_shaul@rambam.health.org.il", 
            "last_name": "Roni Shaul, M.D", 
            "phone": "972-502063333"
        }, 
        "overall_official": {
            "affiliation": "Rambam medical center, Mayers childrens hospital", 
            "last_name": "Butbul Yonatan, M.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The number of gastrointestinal adverse effect  will be measured 3 months before starting the intervention and after 3 months patients will received either placebo or probiotics the measures will be :\nNumber of days with at least one episode of loose stool.\nNumber of days with abdominal pain not related to FMF attacks.", 
            "measure": "The number of gastrointestinal adverse effect related to colchicine therapy after adding probiotics to colchicine therapy.", 
            "safety_issue": "No", 
            "time_frame": "6 months after enrollment assumed to be at 12/2014"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02021084"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rambam Health Care Campus", 
            "investigator_full_name": "yonatan butbul MD", 
            "investigator_title": "Butbul Aviel Yonatan", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The number of attacks will be measured 3 months before starting the intervention and after 3 months patients will received either placebo or probiotics .\nAttacks will defined as fever with one of the above : a. abdominal pain b.pleuritic chest pain c.arthritis d.erysipelas like .", 
            "measure": "Number of  FMF attacks after adding the probiotics to the  colchicine therapy", 
            "safety_issue": "No", 
            "time_frame": "6 months after enrollment assumed to be at 12/2014"
        }, 
        "source": "Rambam Health Care Campus", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rambam Health Care Campus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}